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In patients supported with mechanical circulatory sup-
port (MCS), pump thrombosis is one of the most devastating 
complications associated with high morbidity and mortality.1 
Therefore, it is clear that these patients should receive antico-
agulation (class I recommendation).2 Despite the development 
of new anticoagulant agents, unfractionated heparin (UFH) 
continues to be the anticoagulant of choice, especially in the 
early postoperative phase in which close titration is required.3 
It is well known that the risk of heparin-associated bleeding 
increases with heparin dose, and by recent surgery, or invasive 
procedures.4 Although the use of UFH is unquestioned, moni-
toring remains a matter of discussion. Traditionally, in percu-
taneous coronary intervention or cardiac surgery, the effect of 
UFH is monitored by the activated partial thromboplastin time 
(aPTT) or the activated clotting time (ACT), when higher doses 
of UFH are used in conjunction with extracorporeal bypass.
Although the 2013 Guidelines for MCS by the International 
Society for Heart and Lung Transplantation do not recommend 
specific measurement methods for monitoring of UFH, the 
authors refer to targeted aPTT levels2; similarly, practical clinical 
management instructions5 or the American Heart Association/
American College of Cardiology guidelines on patients with 
non-ST elevation acute coronary syndromes6 or valvular heart 
disease7 refer to target levels of aPTT. Although aPTT seems to 
be the standard criterion, it is known that aPTT is susceptible to 
physiologic and nonphysiologic factors and may underestimate 
or overestimate the level of anticoagulation. For this reason, 
plasma heparin assays—which determine the anticoagulation 
activity of UFH by measuring the ability of heparin-bound 
antithrombin to inhibit FXa—have been proposed.8,9 Published 
data suggest that anti-Xa monitoring achieves therapeutic anti-
coagulation more rapidly, maintains the values within the goal 
range for a longer time, and requires fewer adjustments in dos-
age and repeated tests10; further, the aPTT is impacted more 
frequently by preanalytic compared with anti-Xa.11
Patients with ventricular assist device (VAD) have an 
increased bleeding and thrombotic risk.12 An increased bleed-
ing risk is associated with the loss of high-molecular-weight 
multimers of von Willebrand factor, which is caused by the 
high shear stress at the VAD site. Clot formation on the VAD 
may cause embolic stroke and/or pump malfunction. Thus, 
reliable monitoring of anticoagulation is mandatory to avoid 
overanticoagulation or underanticoagulation. As a conse-
quence, the validity of aPTT as a measure for therapeutic UFH 
levels in patients supported with VADs should be questioned. 
In this issue, Sieg et al.13 describe their retrospective experi-
ence, using an anti-XA anticoagulation protocol in a small 
population of adult patients receiving peripheral VAD. Patients 
were stratified, based on the monitoring of anticoagulation, by 
using aPTT or anti-Xa values. Only 43% of patients monitored 
with aPTT and 69% monitored with anti-Xa were within the 
targeted therapeutic range of UFH. Patients monitored by aPTT 
had increased bleeding and thrombotic event rates compared 
with patients monitored by anti-Xa assay. However, target anti-
Xa in this protocol (0.2–0.4 IU/ml) was significantly lower than 
target anti-Xa usually reported in other studies (0.3–0.7 IU/ml).
These data are in line with a recent prospective study by 
Adatya et al., evaluating the relationship between anti-Xa and 
aPTT for the monitoring of UFH in 38 patients with continu-
ous-flow left VADs. In this study, anti-Xa and aPTT levels were 
discordant in 74.4% of cases, and it was suggested that anti-Xa 
monitoring would provide a more accurate estimate of heparin 
concentration.14
Monitoring UFH using anti-Xa assay may also be of particu-
lar advantage in pediatric patients.3,15–17 Recently, Liveris et al.18 
have shown that the anti-Xa assay was better correlated with 
heparin dosing than the aPTT or ACT in pediatric extracor-
poreal membrane oxygenation, suggesting that anti-Xa assay 
may be a more valuable monitor of heparin administration.18 
Although still no uniform evidence-based guidelines exist on 
the optimal method for monitoring UFH therapy, many clini-
cians use anti-FXa assays preferentially in young children and 
in pediatric intensive care units.19
In conclusion, the ideal monitoring of UFH therapy remains 
a matter of discussion, and all methods, including aPTT, ACT, 
and anti-Xa, have their limitations. The new data by Sieg et al. 
further suggest that the anti-Xa assay may be more reliable than 
the aPTT in patients with VAD and emphasize the need for more 
prospective studies looking at the optimal method to monitor 
UHF in adult and pediatric patients with MCS. Until uniform, 
evidence-based guidelines are available, we fully support the 
conclusion of Sieg et al.13 that an individualized anticoagula-
tion protocol in the complex scenario of each patient on VAD 
is warranted.
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